- Home
- BOLD vs TPST Comparison
BOLD vs TPST Comparison
Compare BOLD & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- TPST
- Stock Information
- Founded
- BOLD 2018
- TPST 2011
- Country
- BOLD United States
- TPST United States
- Employees
- BOLD N/A
- TPST N/A
- Industry
- BOLD
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- BOLD
- TPST Health Care
- Exchange
- BOLD Nasdaq
- TPST Nasdaq
- Market Cap
- BOLD 30.3M
- TPST 33.0M
- IPO Year
- BOLD 2024
- TPST N/A
- Fundamental
- Price
- BOLD $1.17
- TPST $6.95
- Analyst Decision
- BOLD Buy
- TPST Hold
- Analyst Count
- BOLD 3
- TPST 3
- Target Price
- BOLD $4.00
- TPST $30.00
- AVG Volume (30 Days)
- BOLD 283.9K
- TPST 90.3K
- Earning Date
- BOLD 08-11-2025
- TPST 08-07-2025
- Dividend Yield
- BOLD N/A
- TPST N/A
- EPS Growth
- BOLD N/A
- TPST N/A
- EPS
- BOLD N/A
- TPST N/A
- Revenue
- BOLD N/A
- TPST N/A
- Revenue This Year
- BOLD N/A
- TPST N/A
- Revenue Next Year
- BOLD N/A
- TPST N/A
- P/E Ratio
- BOLD N/A
- TPST N/A
- Revenue Growth
- BOLD N/A
- TPST N/A
- 52 Week Low
- BOLD $1.00
- TPST $5.35
- 52 Week High
- BOLD $4.72
- TPST $30.03
- Technical
- Relative Strength Index (RSI)
- BOLD N/A
- TPST 46.97
- Support Level
- BOLD N/A
- TPST $7.06
- Resistance Level
- BOLD N/A
- TPST $7.64
- Average True Range (ATR)
- BOLD 0.00
- TPST 0.27
- MACD
- BOLD 0.00
- TPST 0.02
- Stochastic Oscillator
- BOLD 0.00
- TPST 31.91
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.